Abstract: The present invention provides a kind of inherent flame retardant rigid polyurethane foam. The production formula comprises 100 to 105 pbw of polyether polyol and reactive phosphorus-containing flame retardant, 2.5 to 3.5 pbw of amine catalyst, 0.8 to 2.5 pbw of tertiary amine catalyst, 0.8 to 2.5 pbw of foam stabilizer, 0.5 to 1.5 pbw of blowing agent, 135 to 150 pbw of isocyanates, and 0.05 to 0.1 pbw of organo-metallic catalyst, wherein the reactive phosphorus-containing flame retardant is 9,10-dihydro-9-oxa-10-phosphaphenanthrene-4-hydroxybenzyl alcohol. The active monomers containing flame retarding elements are introduced into main chain and side chain of PU for modification, which permanently improves the flame retardancy of PU without obvious effect on other performance of PU matrix.
Abstract: A membrane photobioreactor for treating nitrogen and phosphorus that are out of limits in a biogas slurry and treating method thereof, relating to biogas slurry treatment. The membrane photobioreactor for treating nitrogen and phosphorus that are out of limits in a biogas slurry is provided with a biogas slurry storage tank, peristaltic pumps, a microalgae cultivating tank, an air pump, a membrane photobioreactor and a hollow fiber membrane.
Type:
Application
Filed:
July 30, 2014
Publication date:
February 16, 2017
Applicant:
XIAMEN UNIVERSITY
Inventors:
Qingbiao Li, Xi Chen, Ning He, Yuanpeng Wang, Liang Shen, Haitao Wang
Abstract: The present application provides a method for simultaneously synthesizing a biological flocculant with polysaccharide and ?-PGA as the active components by using Bacillus licheniformis. Bacillus licheniformis is inoculated to a slant culture medium to be cultured; a single colony on a fresh plate is inoculated to a seed culture medium to be cultured; and a seed fermentation broth is inoculated to a fermentation culture medium to be cultured, and then the biological flocculant having two different components is obtained. The flocculant synthesized in the present invention is high in activity and good in thermal stability; and especially, the flocculation effect of polysaccharide is relatively superior under acidic and neutral conditions, and the flocculation activity of ?-PGA is relatively higher under neutral and alkaline environments, which can satisfy a relatively large pH application range.
Type:
Application
Filed:
July 30, 2014
Publication date:
February 2, 2017
Applicant:
XIAMEN UNIVERSITY
Inventors:
Ning He, Haosheng Yao, Yu Liu, Wencheng Yu, Shan Yan, Yuanpeng Wang, Qingbiao Li
Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
Abstract: The present invention provides a POSS-containing in-situ composite nanogel with magnetic responsiveness and the method for preparing the same, wherein POSS-containing macromolecule capable of polymerizing and metal-coordination complexing is synthetized to complex with iron salt, Fe2+/Fe3+ salts are in-situ deposited via chemical coprecipitation, and crosslinking agent and initiator are added to induce polymerization so that POSS-containing nanogel ranges with magnetic responsiveness is obtained. The present invention is of professional design, feasible technique and simple operation, and prepared nanogel magnetic particles are well dispersed with excellent magnetic responsiveness, which possesses a good application prospect in medical diagnosis, sensor, catalyst carrier and biomaterial.
Abstract: Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.
Abstract: Provided is a truncated L1 protein of Human Papillomavirus (HPV) Type 52 which, compared to a wild type HPV52 L1 protein, is truncated by 27-42 amino acids at the N-terminal. Also provided are a coding sequence of the truncated HPV52 L1 protein, a virus-like particle (VLP) comprising the protein, and a method of preparing the protein and the VLP using an E. coli expression system. The truncated HPV52 L1 protein and an assembled VLP can be used to prevent an HPV52 infection and a disease caused by HPV52 infection, such as cervical cancer.
Abstract: A new approach for preparation and use of adhesive for metal and fabric bonding is proposed in this invention. Generally, 80-120 g of epoxy resin, 10-30 g of reactive diluent, 0.5-5 g siliane coupling agent, 0.5-5 g metallic oxide nanopowder and 35-60 g curing agent are applied in the formula. With the treatment of silane coupling agent and the mixture of phosphoric acid and nitric acid respectively, the active groups are introduced onto the surface of the metal and the fabric, which enhanced the adhesive strength of metal/fabric interface. Simultaneously, the brittleness, poor cracking and impact resistance of the traditional epoxy adhesive are also optimized by using the method of this invention, which is easy to operate and widely used.
Abstract: The present invention relates to monoclonal antibody specifically binding to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No.
Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 16, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.
Type:
Grant
Filed:
April 29, 2008
Date of Patent:
August 30, 2016
Assignees:
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen University
Abstract: The present invention provides a fluorine-containing self-lubricating fabric coating material and method for preparing the same. The coating material consists of 30 to 70 pbw of fluorine resin, 10 to 40 pbw of a curing agent, 5 to 25 pbw of a reactive diluents, 0.5 to 5 pbw of a silane coupling agent and 0.5 to 3 pbw of a silicon surfactant. It is of high fluorine content and high stability. Besides, the coating material system with characteristics of self-lubricating and weather resistance is solvent-free, environmentally friendly, and has wide applications.
Type:
Application
Filed:
August 13, 2014
Publication date:
July 21, 2016
Applicant:
XIAMEN UNIVERSITY
Inventors:
Lizong DAI, Jie MAO, Lingnan CHEN, Yiting XU, Birong ZENG, Wuhui QIU, Cunfeng SONG, Wei'ang LUO, Qilong KANG
Abstract: The present invention provides a method for preparing high-strength cross-linked polymer photonic crystal film by core-shell polymer microspheres via evaporation-induced self assembly. Monodispersed core-shell polymer microspheres are fabricated by emulsifier-free emulsion polymerization, and then the microspheres emulsion is coated onto suitable substrates. Finally, polymer photonic crystal film with long-range ordered is constructed via self assembly. Self-cross-linking between the two units improves the strength of the polymer photonic crystal film, therefore the preparation of large size industrial-grade photonic crystal film is practicable which extends its application on the field of dyeing.
Type:
Application
Filed:
August 13, 2014
Publication date:
July 7, 2016
Applicant:
XIAMEN UNIVERSITY
Inventors:
Lizong Dai, Shirong YU, Conghui Yuan, Long Zhang, Lina Zhong, Cunfeng Song, Yiting Xu, Birong Zeng, Wei'ang Luo
Abstract: Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection.
Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 18, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.
Type:
Grant
Filed:
April 29, 2008
Date of Patent:
June 14, 2016
Assignees:
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen University
Abstract: The present invention discloses a method for detecting multiple single nucleotide variations or polymorphisms in a single reaction tube, and the oligonucleotide, the probe, the set of probes, the kit used, as well as the use thereof. Specifically, it relates to a method for identifying the genotype of multiple single nucleotide variation or SNP sites from the melting temperature of a kind of artificial melting temperature tag sequence (AMTS) and the type of fluorescence labels.
Abstract: Disclosed are nanoparticles comprising octapod iron oxide having eight trigonal bipyramidal arms and a method of preparing the same. The nanoparticles are prepared by heating a mixture of a ferric carboxylate, a carboxylic acid, a chloride salt, water, and a non-polar solvent, to a temperature above about 300° C. Also disclosed is a method of magnetic resonance imaging a tissue in a mammal, comprising use of the aforesaid nanoparticles.
Type:
Application
Filed:
June 3, 2013
Publication date:
May 12, 2016
Applicants:
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV, XIAMEN UNIVERSITY
Abstract: The present invention relates to a method and a kit for detecting nucleic acid sequence variation using melting curve analysis, especially relates to a method and a kit for detecting nucleic acid sequence variation by melting curve analysis using self-quenched probe. Said method provides the characteristics of the self-quenched probe employed, as well as the corresponding nucleic acid amplification conditions, so that the probe can bind to the amplified target sequence, and variations of the target sequence can be detected by melting curve analysis. The present invention also encompasses a kit assembled according to the method described.
Abstract: The present invention relates to an epitope peptide (or a variant thereof) which can be used in the prevention of respiratory syncytial virus (RSV) infection, a recombinant protein comprising the epitope peptide (or a variant thereof) and a carrier protein, and uses of the epitope peptide (or a variant thereof) and the recombinant protein. The present invention also relates to an antibody against the epitope peptide, a cell line for generating the antibody, and uses thereof. Furthermore, the present invention also relates to a vaccine or a pharmaceutical composition comprising the recombinant protein or the antibody according to the invention, for preventing one or more symptoms associated with RSV infection.
Type:
Application
Filed:
March 17, 2014
Publication date:
February 4, 2016
Applicants:
XIAMEN INNOVAX BIOTECH CO., LTD., XIAMEN UNIVERSITY
Inventors:
Zizheng Zheng, Jason S. McLellan, Man Chen, Min Zhao, Liangmin Huang, Barney S. Graham, Ningshao Xia
Abstract: The present invention relates to a truncated L1 protein of Human Papillomavirus (HPV) Type 33, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein and the virus-like particle are useful for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer. The invention also relates to the use of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer.
Abstract: The RNAi target sequences, which could be used for treating AIDS through targeting HIV. Based on the target sequences, recombinant expression vectors, packaging vectors and cells were constructed, which express siRNA and/or miRNA and/or ribozyme and/or antisense oligonucleotide for targeting HIV. And the applications of said recombinant expression vectors, packaging vectors and cells in preparing medicament for treating AIDS.
Type:
Grant
Filed:
August 13, 2012
Date of Patent:
December 29, 2015
Assignees:
XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY LIMITED
Inventors:
Tong Cheng, Tao Zhang, Yali Zhang, Ji Miao, Jun Zhang, Ningshao Xia